A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-ranging Study Evaluating LTI-01 (Single-chain Urokinase Plasminogen Activator, scuPA) in Patients With Infected, Non-draining Pleural Effusions
Latest Information Update: 03 Apr 2023
At a glance
- Drugs LTI 01 (Primary)
- Indications Pleural effusion
- Focus Adverse reactions
- Sponsors Lung Therapeutics
- 27 Sep 2022 Status changed from recruiting to completed.
- 20 Aug 2021 Planned End Date changed from 1 Mar 2022 to 1 Sep 2022.
- 18 Aug 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Mar 2022.